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Abstract
Background: Recent data indicate that loss-of-function mutation in the gene encoding the facilitative glucose
transporter GLUT10 (SLC2A10) causes arterial tortuosity syndrome via upregulation of the TGF-b pathway in the
arterial wall, a mechanism possibly causing vascular changes in diabetes.
Methods: We genotyped 10 single nucleotide polymorphisms and one microsatellite spanning 34 kb across the
SLC2A10 gene in a prospective cohort of 372 diabetic patients. Their association with the development of
peripheral arterial disease (PAD) in type 2 diabetic patients was analyzed.
Results: At baseline, several common SNPs of SLC2A10 gene were associated with PAD in type 2 diabetic patients.
A common haplotype was associated with higher risk of PAD in type 2 diabetic patients (haplotype frequency:
6.3%, P = 0.03; odds ratio [OR]: 14.5; 95% confidence interval [CI]: 1.3- 160.7) at baseline. Over an average follow-up
period of 5.7 years, carriers with the risk-conferring haplotype were more likely to develop PAD (P = 0.007; hazard
ratio: 6.78; 95% CI: 1.66- 27.6) than were non-carriers. These associations remained significant after adjustment for
other risk factors of PAD.
Conclusion: Our data demonstrate that genetic polymorphism of the SLC2A10 gene is an independent risk factor
for PAD in type 2 diabetes.
Background
Peripheral arterial disease (PAD), defined as lower extre-
mity arterial atherosclerosis, is one of most common
diseases of the arteries and is a major complication of
type 2 diabetes [1]. Conventional cardiovascular risk fac-
tors such as aging, smoking, hyperglycemia, hyperten-
sion and dyslipidemia have been shown to be associated
with PAD [1]. However, the increased risk for athero-
sclerotic diseases in diabetic patients can be only par-
tially explained by the conventional risk factors [2]. In
fact, a high heritability for ankle-brachial blood pressure
index (ABI), an index of PAD, has been obtained in
Twin studies in Caucasians [3], indicating that addi-
tional genetic factors might be involved in the pathogen-
esis of PAD. In this respect, the search for genetic
causes of PAD remains limited [4].
Recently, a genetic form of arterial tortuosity syn-
drome (ATS; OMIM 208050) was reported to be caused
by loss-of-function mutations in the SLC2A10 gene
encoding the facilitative glucose transporter GLUT10.
Affected individuals are characterized by tortuosity of
the large and medium-sized arteries, and often resulting
in premature death at a young age [5-8]. The features of
vascular changes observed in ATS were similar to those
described for Loeys-Dietz syndrome (LDS; OMIM
609192), characterized by upregulation of transforming
growth factor (TGF)-b signaling [5]. TGF-b mediates
the downstream the signaling of hyperglycemia-activated
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matrix deposition in vessels exposed to hyperglycemia
[9]. Increased TGF-b signaling also correlates with the
microangiopathic changes and fibrosis seen in diabetic
retinopathy, nephropathy, and peripheral arterial disease
[9-11]. These data indicate that the SLC2A10 gene is a
candidate gene of vascular complications in subjects
with type 2 diabetes.
To explore the association of SLC2A10 genetic poly-
morphism with PAD in type 2 diabetic patients, we
recruited a total of 372 diabetic patients from a Taiwa-
nese population. These patients were followed for the
development of PAD over an average period of
5.7 years. The associations of SLC2A10 genetic variants
with baseline and incident PAD during follow-up were
analyzed.
Methods
Subjects and Phenotype Measurements
This study recruited 372 patients with type 2 diabetes
diagnosed with the WHO criteria of 1998 [12] from the
metabolic clinic of the National Taiwan University Hos-
pital, Taipei, Taiwan. All subjects are Han Chinese by
self-report. Body weight and height were measured to
calculate body mass index (BMI). Seated blood pressure
was measured after at least 5 min of resting. Demo-
graphic data and past medical history including cardio-
vascular, cerebrovascular and peripheral arterial diseases
were documented. PAD was defined as an ankle-brachial
index (ABI) < 0.9 in any of the two limbs, using a hand-
held Doppler ultrasound (Medacord PVL, Medasonics,
Fremont, CA) over brachial and dorsalis pedis or poster-
ior tibial pulses according to the American College of
Cardiology/American Heart Association guideline [13].
The concentrations of plasma glucose, total cholesterol,
and triglyceride were measured in fasting samples by an
autoanalyzer (Hitachi 7250 special, Tokyo, Japan).
HbA1c was measured with high-performance liquid
chromatography (CLC385, Primus Corporation, Kansas
City, MO). All subjects were unrelated and were given
written informed consent. The study protocol was
approved by the Institutional Review Board of the
National Taiwan University Hospital. All participants
a n di n v e s t i g a t o r sw e r eb l i n dt ot h eg e n o t y p i n g
information.
SNP Selection and Genotyping
Genomic DNA was isolated using the PUREGENE DNA
purification system (Gentra Systems, Minneapolis, MN).
A total of 11 polymorphic markers, including 10 SNPs
(rs2425895, rs2143044, rs3092412, rs2235491,
rs2425904, rs2425911, rs3091904, rs1059217, rs6066059,
rs2179357) and one (TGTGTGTGT)n microsatellite,
were selected using the SNPper software http://snpper.
chip.org and were genotyped as previously described
[14]. Samples with failed genotyping were analyzed with
direct sequencing and therefore the genotype success
rate was 100%. The genotyping concordance rate based
on 92 replicates was 98.9%.
Statistical Analysis
Hardy-Weinberg equilibrium tests were carried out
before conducting marker-trait association analyses.
Inter-marker linkage dis-equilibrium (LD) was estimated
by measuring pairwise D′ and r
2 and were displayed
using the Haploview software[ 1 5 ] .T h eS A S / G e n e t i c s
package was used for the single-locus association analy-
sis and allele and genotype p-values were calculated
from Chi-square or Fisher exact tests. Odds ratios (OR)
and 95% confidence intervals (CI) were estimated with
multivariate logistic regression. For haplotype analyses,
we used the score test developed by Schaid et al.a n d
implemented in the Haplo. Stats package http://mayore-
search.mayo.edu/schaid_lab/software.cfm[16]. This
method allows the adjustment for possible confounding
variables. Haplotypes with frequencies less than 0.01
were grouped into rare haplogroups in the regression
analyses. Nominal two-sided P-values were calculated
with simulation for 1,000 times. Cox proportional
hazard models were used to evaluate the risk of devel-
oping PAD by carrying individual haplotypes. The
hazard ratios (HR) comparing the risks of developing
PAD between individuals with and without each specific
haplotype were computed. Potential confounders includ-
ing age, sex, duration of diabetes, BMI, triglyceride, total
cholesterol, HbA1c, systolic blood pressure and current
smoking status were adjusted in these analyses. The
Kaplan-Meier method was employed to estimate the
survival curves for individuals with and without a speci-
fic haplotype. The log-rank test was used to assess the
significance level of the difference between two curves.
These analyses were performed using LIFETEST proce-
dure in the SAS statistical package.
Results
The baseline characteristics of study participants are
summarized in Table 1. At baseline, 27 (7.26%) of 372
type 2 diabetic subjects had PAD. There were significant
differences between patients with or without PAD in
age, duration of diabetes, and systolic blood pressure.
No significant difference was found for other variables
between the two groups.
Eleven polymorphic markers including 10 SNPs and
one microsatellite spanning 34 kb across the SLC2A10
gene were genotyped. All markers were in Hardy-Wein-
berg equilibrium (data not shown). Graphical represen-
tations of these markers in relation to the exon-intron
structure and the LD structure are shown in Figure 1.
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Page 2 of 7The genomic position, gene region, and nucleic acid
compositions of the markers are summarized in Table 2.
We first compared the allele frequencies between type
2 diabetic subjects with and without PAD at baseline.
Eight SNPs showed nominally significant associations
with PAD in type 2 diabetes (Table 2). Among them,
the T allele at rs2179357 showed the strongest associa-
tion with PAD in type 2 diabetic patients (P =2 . 6×1 0
-
4; OR: 3.87; 95% CI: 1.97- 7.58) (Table 2), which
remained significant after applying the Bonferroni cor-
rection for multiple testing. The genotypic odds ratio
was 7.62 (95%CI: 1.91-35.8, P = 0.0003) for the homozy-
gous genotype (TT) and was 4.20 (95% CI: 1.91-7.58, P
= 0.007) for the heterozygous genotype (TC).
Table 1 Characteristics of type 2 diabetic patients
according to absence (-) or presence (+) of PAD at
baseline
PAD (-)
N = 345
PAD (+)
N=2 7
P-value
Age (year) 60.2 ± 11.5 71.4 ± 8.11 < 0.0001
Duration of diabetes (year) 10.7 ± 7.63 16.4 ± 11.2 0.01
Sex (male: female) 177:168 17:10 0.24
BMI (kg/m
2) 24.9 ± 3.32 24.7 ± 3.60 0.86
Triglyceride (mmol/l) 1.74 ± 0.93 1.74 ± 0.93 0.99
Total cholesterol (mmol/l) 5.15 ± 1.01 5.32 ± 0.88 0.40
Hemoglobin A1c (%) 7.67 ± 1.39 7.95 ± 1.13 0.30
Systolic blood pressure (mmHg) 134.3 ± 16.5 145.0 ± 16.5 0.003
Smoker: non-smoker 269:76 21:6 0.98
Figure 1 Graphical representation of SNPs in relation to the exon-intron structure (upper part) and Haploview LD graph of SCL2A10
gene (lower part). The exon regions are shown with filled rectangles and numbered in order. Pairwise LD coefficients D’ × 100 was shown in
each cell (D’ values of 1.0 were not shown). Standard color scheme of Haploview was applied for LD color display (LOD score > 2 and D’ =1i n
bright red; LOD score > 2 and D’ <1 in blue; LOD score <2 and D’ = 1 in shade of pink; LOD score <2 and D’ <1 in white).
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lotype (H4) conferring a strong risk of PAD in type 2
diabetic patients (P = 0.03, OR: 14.5; 95% CI: 1.3-160)
(Table 3). At baseline, 6 of the 27 subjects with PAD
were estimated to be H4 haplotype carriers, whereas
only 39 of the 345 subjects without PAD carried the H4
haplotype. These associations remained significant after
adjustment for possible confounding risk factors includ-
ing age, sex, systolic blood pressures, hemoglobin A1C
(HbA1C) levels, durations of diabetes, BMI, current
smoking status, serum triglyceride, and total cholesterol
levels (Table 4), indicating that the SLC2A10 genetic
polymorphism is an independent risk factor of PAD in
type 2 diabetes.
We next examined whether the risk haplotype affected
the incidence of PAD in type 2 diabetic subjects. Over
an average follow-up period of 5.7 years, 13 (3.76%) of
the 345 diabetic patients without PAD at the baseline
developed PAD. Carriers of risk-conferring haplotype
H4 were more likely to develop PAD than were other
haplotypes during follow-up (P = 0.007; HR: 6.78; 95%
CI: 1.66-27.6) (Table 3). During follow-up, 5 of the 13
incident PAD cases were estimated to be H4 carriers,
whereas H4 haplotype was only present in 34 of the 332
subjects who did not develop PAD. The Kaplan-Meier
curves representing the cumulative incidence of PAD
for individuals with and without carrying the haplotype
H4 is depicted in Figure 2.
To further search for causative variants of SLC2A10,
we performed the direct DNA sequencing of all exons
and flanking intronic sequences of the SLC2A10 gene in
all patients with PAD. No pathogenic mutations other
Table 2 SLC2A10 sequence variants and association with PAD in type 2 diabetic patients at baseline
# ID Position
(kb)
Function Major/
minor allele
Minor allele
frequency
PAD(-) PAD
(+)
Allelic p-value
(adjusted*)
Allele OR*
(95% CI)
Genotype
distribution**
PAD (-) PAD (+)
Genotypic
p-value
(adjusted*)
1 rs2425895 -1.789 5’ upstream G/A 0.067 0.056 0.75 (0.83) 0.87 (0.24-3.13) 301:42:2 24:3:0 1.00 (0.82)
2 (TGTGTGTGT)n -0.208 5’ upstream 3/2 0.24 0.28 0.54 (0.38) 1.37 (0.68-2.80) 198:128:18 14:11:2 0.72 (0.39)
3 rs2143044 10.341 Intron 1 C/T 0.31 0.44 0.03 (0.03) 2.00 (1.04-3.85) 167:141:35 7:16:4 0.05 (0.04)
4 rs3092412 11.720 Intron 1 A/T 0.39 0.56 0.01 (0.005) 2.51 (1.31-4.81) 130:164:51 4:16:7 0.03 (0.006)
5 rs2235491 15.915 Exon 2
Ala206Thr
G/A 0.074 0.13 0.14 (0.036) 3.03 (1.08-8.55) 296:47:2 21:5:1 0.11 (0.05)
6 rs2425904 18.500 Intron 3 T/C 0.37 0.56 0.007 (0.004) 2.58 (1.34-4.98) 133:167:45 3:18:6 0.006 (0.004)
7 rs2425911 21.843 Intron 4 G/C 0.38 0.56 0.01 (0.005) 2.54 (1.32-4.87) 132:164:49 3:8:6 0.009 (0.005)
8 rs3091904 23.079 Intron 4 C/T 0.38 0.57 0.004 (0.002) 2.83 (1.46-5.46) 136:158:51 3:17:7 0.005 (0.002)
9 rs1059217 26.273 3’ UTR C/T 0.37 0.56 0.007 (0.004) 2.58 (1.35-4.95) 185:160:0 9:18:0 0.005 (0.004)
10 rs6066059 29.778 3’ downstream C/T 0.37 0.56 0.005 (0.004) 2.61 (1.36-5.00) 138:161:46 3:18:6 0.004 (0.004)
11 rs2179357 32.708 3’ downstream C/T 0.33 0.57 2.6 × 10
-4
(< 0.0001)
3.87 (1.97-7.58) 160:143:42 4:15:8 0.001 (< 0.0001)
*P-values and odds ratios were adjusted for covariates including age, sex, duration of diabetes, BMI, triglyceride, total cholesterol, HbA1c, systolic blood pressure
and current smoking status.
**Genotype distribution are shown as number (AA: AB: BB); A represents the major allele and B represents the minor allele.
PAD, peripheral artery disease; OR, odds ratio; CI, confidence interval
Table 3 SLC2A10 haplotype analysis for association with baseline, incident, and all PAD in type 2 diabetes
Haplotype Sequence Frequency Baseline PAD association Incident PAD association
P
* OR (95% CI)* P
* HR (95%CI)*
H1 A3TAGCCTTTT 0.051 0.87 1.28(0.07-22.8) 0.89 1.17(0.13-10.4)
H2 G3CTGTGCCCC 0.499 0.01 0.20(0.05- 0.75) 0.80 1.20(0.30- 4.72)
H3 G2TAGCCTTTT 0.118 0.08 4.20(0.82- 21.6) 0.29 0.42(0.09- 2.06)
H4 G3TAGCCTTTT 0.063 0.03 14.5(1.3-160) 0.007 6.78(1.66- 27.6)
H5 G2CAACCTTTT 0.041 0.97 1.07(0.04- 29.5) 0.99 1.8 × 10
-7 (0-∞)
H6 G2CTGTGCCCC 0.026 0.42 5.4 × 10
-4(0- 40159) 0.66 0.60(0.06-5.99)
H7 G3TAGCCTTTC 0.023 0.48 1.7 × 10
-6 (0-∞) 0.87 1.22(0.10- 14.5)
H8 G3CTGTGCCCT 0.015 0.40 7.67(0.07- 894) 0.34 3.01(0.31- 29.0)
Rare haplotypes 0.15 0.26 1.36(0.80-2.31) 0.99 4.8 × 10
-6 (0-∞)
* P-values, odds ratios, and hazard ratios were adjusted for covariates including age, sex, duration of diabetes, body mass index, triglyceride, total cholesterol,
hemoglobin A1C, systolic blood pressure and current smoking status.
PAD, peripheral artery disease; OR, odds ratio; HR, hazard ratio, CI, confidence interval
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shown).
Discussion
This study showed that common SLC2A10 genetic var-
iants were associated with the development of PAD in
type 2 diabetic patients independent of all known risk
factors for PAD including age, sex, smoking, lipids,
and blood pressures. The association was observed at
baseline and was further replicated during follow-up
study. These data suggest the SLC2A10 gene plays a
significant role in the pathogenesis of PAD in diabetic
patients.
The SLC2A10 gene encodes GLUT10, a facilitative
glucose transporter. The facilitated glucose transporter
(GLUT) mediated the uptake of several monosacchar-
ides including glucose, fructose, mannose, galactose, and
glucosamine [17]. The physiological function of
GLUT10 was unclear until recently, when a genetic
form of arterial tortuosity syndrome was identified by a
loss-of-function mutation in the SLC2A10 gene [5-8],
with a pathology characterized by upregulation of TGF-
b signaling in the vascular walls. TGF-b signaling is one
of the final common pathways linking hyperglycemia
and vascular complications in individuals with diabetes
mellitus [9]. In addition, impaired uptake of monosac-
charides, a function of GLUT10, may hinder glycosyla-
tion, which is an important step for the production of
functional glycoproteins and proteoglycans [5]. Glyco-
proteins and proteoglycans are essential structural com-
ponents of the arterial wall and connective tissue. In
support of this notion, we recently demonstrated that
mutation in the SLC2A10 gene in mice causes irregular
shape of large and medium-sized arteries, characterized
by markedly increased elastic fibers and intimal
endothelial hypertrophy [18]. These data further support
the role of SLC2A10 gene in the pathogenesis of diabetic
vascular complications.
The SNPs with significant associations with PAD in
our study are located in non-coding regions within a
single LD block spanning from intron 1 to the 3′ down-
stream of SLC2A10 gene. One non-synonymous SNP
rs2235491 (Ala260Thr, exon 2) was in strong LD with
rs2179357 (D′ = 0.82) but did not show significant asso-
ciation with PAD, which may be attributed to its low
frequency in the Taiwanese population. Previous study
has provided evidence that the rs2235491 Ala/Ala car-
riers exhibit higher fasting plasma insulin level and
higher area-under-curve of insulin levels after glucose
loading [19]. The rs2235491 Ala allele might contribute
to the vascular complication in type 2 diabetes via asso-
ciated hyperinsulinemia. A larger sample size would be
required to clarify whether this putatively functional var-
iation is the causal variant. In our study, the association
is strongest for the SNPs that are located near the 3′
UTR, downstream of the SLC2A10 gene. However,
Table 4 Multivariate regression analyses of the SLC2A10 haplotype H4 with PAD in type 2 diabetes
Risk factors Effect estimate OR (95% CI) P-values
Age (per year) 0.0812 1.09(1.04,1.13) 3×1 0
-4
Male -0.0456 0.91(0.38,2.19) 0.83
Hemoglobin A1C (per 1%increase) 0.1046 1.11(0.91,1.36) 0.31
Duration of diabetes (per year) 0.0467 1.05(1,1.1) 0.04
Triglyceride
(per increase of 1mM)
0.2118 1.24(0.79,1.92) 0.34
Total cholesterol
(per increase of 1mM)
-0.1952 0.82(0.54,1.26) 0.36
Systolic blood pressure
(per 1 mmHg increase)
0.0463 1.05(1.03,1.07) 1.9 × 10
-5
Current smoker -0.2913 0.56(0.22,1.44) 0.22
Body mass index (per kg/m
2 increase) -0.0564 0.95(0.83,1.08) 0.39
H4 haplotype 3.4171 30.47(4.47-208.5) 5×1 0
-4
PAD, peripheral artery disease; OR, odds ratio; CI, confidence interval
Figure 2 Cumulative probability of PAD in type 2 diabetic
patients with and without haplotype H4.
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this region failed to reveal any conserved regulatory
motif among different species to support the functional
consequences [20].
Our results demonstrate that variation of the SLC2A10
g e n en o to n l yr e s u l t si nar a r ev a s c u l a rs y n d r o m eb u t
also is associated with susceptibility to common vascular
complications in type 2 diabetes. It is interesting to note
that prevalence of PAD and amputation rate in type 2
diabetes is lower in Chinese populations as compared to
Caucasians and Indians [21-24]. Using data from the
HapMap database, the risk at the rs2179357 T allele,
which is in strong LD with other risk alleles in our
study, is present in 81% of Caucasians but only in 44%
of Han Chinese [24]. Whether this difference explains
the lower incidence of PAD in type 2 diabetic Asians
remains to be further studied.
There are certain limitations of this study. First,
although a total of 1,967 person-years of follow-up were
accumulated in this study, the sample size is relatively
small and the incident cases were limited. Therefore, the
association may be seriously influenced by random fluc-
tuation. We calculated the power of this study to detect
variants with various frequencies and odds ratio. For
345 controls and 27 cases, we will have a statistical
power of 0.8 to detect an odds ratio of 3.0, 3.6, 4.6 and
10.0 for a target allele or haplotype frequency of 0.2, 0.1,
0.05 and 0.01, respectively, assuming a type I error rate
of 0.05 (Additional File 1: Supplemental Figure S1). Sec-
ond, the result has not been replicated in an indepen-
dent study. Although the association in baseline was
replicated in longitudinal follow-up, it cannot be viewed
as a true independent replication. Thirdly, population
stratification may arise when samples are drawn from
structure populations. However, our study participants
were all Han Chinese by self-report. Previous research
has demonstrated that genotype distribution in Han
Chinese in Taiwan is highly homogenous [25]. The high
homogeneity mitigates the possibility of spurious asso-
ciation. Lastly, the drop-out rate in this study is substan-
tial (31.11% in H4 haplotype carriers and 31.11% in non-
H4 haplotype carriers). Although there is no difference
in drop-out rate or drop-out reasons between two
groups (data not shown), whether the high drop-out
rate introduces bias to this study is not known.
Conclusions
We identified common SLC2A10 genetic variants con-
ferring strong and independent risk on development of
PAD in type 2 diabetic patients. The present report
indicates an important role of the GLUT10 transporter
in PAD development in diabetic patients. Whether or
not the SLC2A10 genetic polymorphism contributes to
other micro- or macrovascular complications merits
further investigation.
Additional material
Additional file 1: Supplemental Figure S1. The statistical power of
current study to detect a risk allele or haplotype with different odds
ratios and frequencies with type I error rate of 0.05.
Acknowledgements
We thank all the patients for their cooperation in this study. The authors are
grateful for the computing assistance from Ms. Hui-Yi Kao and Yu-Jane Tsai.
The support from the National Genotyping Center is acknowledged. This
research is supported by grants from the National Science Council of Taiwan
(NSC-93-B-002-005; NSC-94-3112-B-002-019 to LMC, NSC-95-3112-B-001-010
to YTC) and the Genomics and Proteomics Program, Academia Sinica,
Taiwan (to YTC).
Author details
1Department of Internal Medicine, National Taiwan University Hospital,
Taipei, Taiwan.
2Genomics Research Center, Academia Sinica, Taipei, Taiwan.
3Division of Biostatistics and Bioinformatics, National Health Research
Institutes, Zhunan, Taiwan.
4Division of Biotechnology and Pharmaceutical
Research, National Health Research Institutes, Zhunan, Taiwan.
5Institute of
Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
6Graduate Institute of
Clinical Medicine, National Taiwan University College of Medicine, Taipei,
Taiwan.
Authors’ contributions
YDJ, YCC, and YFC participated in the design of the study, analysis of results,
and manuscript writing. TJC and HYL provided the sample and clinical data
of study participants. WHL finished the genotyping work. HYY and YTC
participated in the interpretation of study. LMC participated in the design of
the study, interpretation of results, and manuscript revision. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 11 August 2009 Accepted: 25 August 2010
Published: 25 August 2010
References
1. Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR: UKPDS 59:
hyperglycemia and other potentially modifiable risk factors for
peripheral vascular disease in type 2 diabetes. Diabetes Care 2002,
25:894-899.
2. Keen H, Clark C, Laakso M: Reducing the burden of diabetes: managing
cardiovascular disease. Diabetes Metab Res Rev 1999, 15:186-196.
3. Carmelli D, Fabsitz RR, Swan GE, Reed T, Miller B, Wolf PA: Contribution of
genetic and environmental influences to ankle-brachial blood pressure
index in the NHLBI Twin Study. National Heart, Lung, and Blood
Institute. Am J Epidemiol 2000, 151:452-458.
4. Gudmundsson G, Matthiasson SE, Arason H, Johannsson H, Runarsson F,
Bjarnason H, et al: Localization of a Gene for Peripheral Arterial Occlusive
Disease to Chromosome 1p31. Am J Hum Genet 2002, 70:586-592.
5. Coucke PJ, Willaert A, Wessels MW, Callewaert B, Zoppi N, De Backer J, et al:
Mutations in the facilitative glucose transporter GLUT10 alter
angiogenesis and cause arterial tortuosity syndrome. Nat Genet 2006,
38:452-457.
6. Drera B, Guala A, Zoppi N, Gardella R, Franceschini P, Barlati S, et al: Two
novel SLC2A10/GLUT10 mutations in a patient with arterial tortuosity
syndrome. Am J Med Genet A 2007, 143:216-218.
7. Zaidi SH, Meyer S, Peltekova VD, Lindinger A, Teebi AS, Faiyaz-Ul-Haque M:
A novel non-sense mutation in the SLC2A10 gene of an arterial
tortuosity syndrome patient of Kurdish origin. Eur J Pediatr 2008.
Jiang et al. BMC Medical Genetics 2010, 11:126
http://www.biomedcentral.com/1471-2350/11/126
Page 6 of 78. Callewaert BL, Willaert A, Kerstjens-Frederikse WS, De Backer J, Devriendt K,
Albrecht B, et al: Arterial tortuosity syndrome: clinical and molecular
findings in 12 newly identified families. Hum Mutat 2008, 29:150-158.
9. Brownlee M: The Pathobiology of Diabetic Complications. A Unifying
Mechanism. Diabetes 2005, 54:1615-1625.
10. Ziyadeh FN: Mediators of Diabetic Renal Disease: The case for TGF-b as
the major mediator. J Am Soc Nephrol 2004, 15:S55-S57.
11. Chiarelli F, Santilli F, Mohn A: Role of growth factors in the development
of diabetic complications. Hormone Research 2000, 53:53-67.
12. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes
mellitus and its complications. Part 1:diagnosis and classification of
diabetes mellitus provisional report of a WHO consultation. Diabet Med
1998, 15:539-553.
13. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al:
ACC/AHA 2005 Guidelines for the Management of Patients With
Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and
Abdominal Aortic): Executive Summary A Collaborative Report From the
American Association for Vascular Surgery/Society for Vascular Surgery,
Society for Cardiovascular Angiography and Interventions, Society for
Vascular Medicine and Biology, Society of Interventional Radiology, and
the ACC/AHA Task Force on Practice Guidelines (Writing Committee to
Develop Guidelines for the Management of Patients With Peripheral
Arterial Disease) Endorsed by the American Association of
Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and
Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society
Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006,
47:1239-1312.
14. Lin WH, Chuang LM, Chen CH, Yeh JI, Hsieh PS, Cheng CH, et al: An
association study of genetic polymorphisms of SLC2A10 gene and type
2 diabetes in Taiwanese population. Diabetologia 2006, 49:1214-1221.
15. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of
LD and haplotype maps. Bioinformatics 2005, 21:263-265.
16. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA: Score tests for
association between traits and haplotypes when linkage phase is
ambiguous. Am J Hum Genet 2002, 70:425-434.
17. Mueckler M: Family of glucose-transporter genes. Implications for
glucose homeostasis and diabetes. Diabetes 1990, 39:6-11.
18. Cheng CH, Kikuchi T, Chen YH, Sabbagha NG, Lee YC, Pan HJ, et al:
Mutations in the SLC2A10 gene cause arterial abnormalities in mice.
Cardiovasc Res 2008.
19. Andersen G, Rose CS, Hamid YH, Drivsholm T, Borch-Johnsen K, Pedersen O:
Genetic variation of the GLUT10 glucose transporter (SLC2A10) and
relationship to type 2 diabetes and intermediary traits. Diabetes 2003,
52:2445-2448.
20. Xie X, Lu J, Kulbokas EJ, Golub TR, Mootha V, Lindblad-Toh K, et al:
Systematic discovery of regulatory motifs in human promoters and 3′
UTRs by comparison of several mammals. Nature 2005, 434:338-345.
21. Chaturvedi N, Stevens LK, Fuller JH, Lee ET, Lu M: Risk factors, ethnic
differences and mortality associated with lower-extremity gangrene and
amputation in diabetes. The WHO Multinational Study of Vascular
Disease in Diabetes. Diabetologia 2001, 44(Suppl 2):S65-71.
22. Beks PJ, Mackaay AJ, de Neeling JN, de Vries H, Bouter LM, Heine RJ:
Peripheral arterial disease in relation to glycemic level in an elderly
Caucasian population: the Hoorn study. Diabetologia 1995, 38:86-96.
23. Premalatha G, Shanthirani S, Deepa R, Markovitz J, Mohan V: Prevalence
and risk factors of peripheral vascular disease in a selected south India
population. Diabetes Care 2000, 23:1295-1300.
24. The International HapMap Consortium: The International HapMap Project.
Nature 2003, 426:789-796.
25. Yang HC, Lin CH, Hsu CL, Hung SI, Wu JY, Pen WH, Chen YT, Fann CS: A
comparison of major histocompatibility complex SNPs in Han Chinese
residing in Taiwan and Caucasians. J Biomed Sci 2006, 13:489-98.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2350/11/126/prepub
doi:10.1186/1471-2350-11-126
Cite this article as: Jiang et al.: SLC2A10 genetic polymorphism predicts
development of peripheral arterial disease in patients with type 2
diabetes. SLC2A10 and PAD in type 2 diabetes. BMC Medical Genetics
2010 11:126.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Jiang et al. BMC Medical Genetics 2010, 11:126
http://www.biomedcentral.com/1471-2350/11/126
Page 7 of 7